Founded in 2004 and located in the Greater New York area, TheraSource's R&D unit resides at The Feinstein Institute for Medical Research and is currently focused on developing newly-discovered molecules to treat patients with ischemic acute kidney injury (AKI) and acute radiation injury. The company's research team consists of 9 scientists with MD or PhD degrees in multidisciplinary areas, and the company possesses 14 utility patents covering 5 molecules to treat selected inflammatory human diseases. TheraSource's founder and scientists have demonstrated the efficacy of several newly-discovered molecules in preclinical studies of various medical conditions, leading to over 250 peer-reviewed publications.